Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (32827)	11/5/2009 3:48:02 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 52153

Not sure if I understand the ? relating to mfg. cost, would have to listen to call again. From what I recall, MITI is currently negotiating with major firm to produce the dosage, but they have enough supply currently to complete current phase testing. The CEO alluded to the fact it will be a major firm undertaking the future mfg. project. My assumption is that MEDI didn't have the capacity to tie up their facility since they would be turning over the program to MITI. (At least I hope that is the root cause of the cancellation). As for my earlier comment about volume, until about 1:30 EST, the trading volume was around 50,000 shares, however in the last two hours the volume jumped by nearly 275,000 with several blocks crossing........closing action today might tip the hand as to what WS is thinking about upcoming data.